retatrutide and bpc 157 BPC-157 5mg Retatrutide 10mg — Triple Receptor

Amylin/Calcitonin Receptor Agonism (cagrilintide) Delays gastric emptying, reduces postprandial glucagon, and strongly promotes satiety Modulates appetite-regulating centers in the hindbrain, hypothalamus, and brain reward circuits, directly influencing food intake and choice May transiently activate the renin-angiotensin-aldosterone system with dose escalation, but without blood pressure or electrolyte derangements GLP-1 Receptor Agonism (semaglutide) Stimulates glucose-dependent insulin secretion and suppresses glucagon release to improve glycemic control Reduces appetite and ad libitum energy intake, with central effects on GLP-1R-expressing nuclei in hypothalamus and brainstem Delays gastric emptying and increases satiety, contributing to progressive bodyweight loss Pharmacokinetic Profile Route of Administration Subcutaneous Dosing Frequency Once weekly Route of Administration : Subcutaneous Injection Dosing Frequency: Once weekly Half -life: Cagrilintide: 7-8 days

longer-term storage at -20C to -80C depending on institutional standards

or Have intolerable adverse effects associated with allopurinol treatment requiring treatment discontinuation and have trialled probenecid at doses up to 2 g per day or to a maximum tolerated dose

This means fewer injections are needed compared to cyanocobalamin, which is cleared from the body more rapidly